Rearrangements of MLL (encoding lysine-specific methyltransferase 2A and officially known as KMT2A; herein referred to as MLL to denote the gene associated with mixed-lineage leukemia) generate MLL fusion proteins that bind DNA and drive leukemogenic gene expression. This gene expression program is dependent on the disruptor of telomeric silencing 1-like histone 3 lysine 79 (H3K79) methyltransferase DOT1L, and small-molecule DOT1L inhibitors show promise as therapeutics for these leukemias. However, the mechanisms underlying this dependency are unclear. We conducted a genome-scale RNAi screen and found that the histone deacetylase SIRT1 is required for the establishment of a heterochromatin-like state around MLL fusion target genes after DOT1L inhibition. DOT1L inhibits chromatin localization of a repressive complex composed of SIRT1 and the H3K9 methyltransferase SUV39H1, thereby maintaining an open chromatin state with elevated H3K9 acetylation and minimal H3K9 methylation at MLL fusion target genes. Furthermore, the combination of SIRT1 activators and DOT1L inhibitors shows enhanced antiproliferative activity against MLL-rearranged leukemia cells. These results indicate that the dynamic interplay between chromatin regulators controlling the activation and repression of gene expression could provide novel opportunities for combination therapy.
INTRODUCTION
Eukaryotic genomes are intricately organized into chromatin, which is composed of genomic DNA wrapped around nucleosomes and packaged in a highly orchestrated fashion. One mode of regulation that controls chromatin organization is the covalent modification (such as acetylation and methylation) of specific amino acid residues in histones found within the nucleosomes 1 . These post-translational histone modifications are known to modulate the local structure of chromatin and to influence gene expression by regulating the accessibility of gene loci to transcriptional machinery 2 . For example, acetylation of histone H3 lysine 9 (H3K9) is enriched in more-accessible chromatin regions designated for active gene transcription. In contrast, methylation of H3K9 is associated with tightly packaged and repressed genomic regions known as heterochromatin 3 . The dynamic remodeling of histone modifications by nuclear proteins including histone acetyltransferases, deacetylases, and methyltransferases, as well as by demethylases, ensures appropriate gene expression during cellular division and organismal development.
Although most histone modifications are found on the exposed histone N-terminal tails, methylation of H3K79 is present on the surface of the highly structured nucleosome core 4 . Thus far, the only known enzyme that catalyzes the methylation of H3K79 is DOT1L, which was initially identified in S. cerevisiae 5, 6 . Recent genome-wide analysis of the mammalian epigenome have shown that H3K79 methylation is broadly associated with actively transcribed genes and is not frequently found in intergenic regions [7] [8] [9] . The interaction between DOT1L and a number of nuclear protein complexes involved in the control of gene expression further supports the relationship between H3K79 methylation and gene expression [10] [11] [12] [13] [14] [15] [16] [17] . However, recent studies have shown that genetic inactivation of Dot1l and loss of all H3K79 methylation in mouse models does not lead to widespread collapse of transcription 8 . Thus, the exact biological function of DOT1L and H3K79 methylation in the control of mammalian gene expression remains unclear.
An essential role for DOT1L and H3K79 methylation has been documented in leukemias with rearrangement of the mixed-lineage leukemia gene (MLL-r leukemias), which accounts for approximately 5-10% of human acute leukemia cases and is generally associated with poor prognosis 18 . Studies using mouse genetic models have shown that leukemia cells driven by MLL-r are highly dependent on Dot1l for leukemia initiation and maintenance, whereas many other types of transformed hematopoietic cells are insensitive to complete loss of DOT1L and H3K79 methylation 8, [19] [20] [21] [22] [23] . Epigenomic studies have revealed that MLL fusion targets (genes directly bound by MLL fusion proteins) are associated with aberrantly high levels of H3K79 dimethylation (H3K79me2) in leukemias characterized by MLL-r [24] [25] [26] . These MLL fusion targets include developmental genes such as MEIS1 and HOXA-cluster genes, which are known to induce leukemia if ectopically expressed 27 . Because DOT1L interacts with multiple MLL translocation partners such as AF9, ENL, and AF10, it has been suggested that these MLL fusion proteins may drive ectopic gene expression through recruiting excessive DOT1L activity to their target loci [10] [11] [12] [13] [14] [15] [16] 28 . These previous discoveries have established a foundation for diseasespecific epigenetic therapies against the highly malignant MLL-r leukemias. Indeed, small-molecular inhibitors of DOT1L (for example, EPZ4777, EPZ5676 and others) have been developed, one of which is currently undergoing phase 1 clinical trials [29] [30] [31] [32] [33] [34] . Despite the promising progress toward DOT1L inhibitor therapy for individuals with MLL-r leukemia, the exact mechanisms by which DOT1L and H3K79 methylation maintain leukemic gene expression remain elusive. An understanding of the unique subordination of the MLL-r leukemic program to DOT1L could uncover additional therapeutic opportunities and provide information regarding the fundamental function of DOT1L and H3K79 methylation in mammalian gene regulation.
Here we conducted a genome-scale RNAi screen in mouse MLL-AF9 leukemia cells engineered to conditionally excise Dot1l so we could identify genes that, when suppressed, would rescue Dot1l dependence. This unbiased approach discovered sirtuin 1 (encoded by Sirt1), a mammalian ortholog of the yeast Sir2 histone deacetylase 35, 36 , to be a critical antagonist of DOT1L in MLL-r leukemia. Mechanistically, we found that inhibition of DOT1L in MLL fusion leukemias leads to a SIRT1-dependent decrease of H3K9 acetylation, gain of H3K9 methylation and loss of chromatin accessibility at MLL fusion target genes. Thus SIRT1 is necessary for acquisition of a repressed chromatin state upon DOT1L inhibition. This led us to demonstrate the potential for combination of SIRT1 activators and DOT1L inhibitors as a novel therapeutic strategy against difficult-to-treat MLL-r leukemias.
RESULTS

Genome-scale RNAi screening identifies Sirt1 as an antagonist of Dot1l
We hypothesized that there are other effectors required for the decrease in MLL fusion-driven gene expression that occurs upon DOT1L inhibition, and that genetic suppression of these effectors would reverse the antiproliferative effect of DOT1L inactivation in MLL fusion-driven leukemias. To identify these negative regulators of the DOT1L pathway, or antagonists of DOT1L, we conducted a pooled screen by introducing a mouse genome-scale shRNA library (containing 92,425 hairpins targeting 16,924 mouse genes) 37, 38 into Dot1l fl/fl -MLL-AF9 leukemic cells 8 harboring tamoxifen-inducible Cre recombinase (CreER) (Fig. 1a) . We confirmed the biallelic excision of Dot1l and loss of H3K79me2 in these cells after induction of Cre recombinase activity by tamoxifen treatment (Fig. 1b) . We then assessed the relative frequencies of each integrated shRNA sequence before and after Dot1l gene excision by massively parallel sequencing (HiSeq). Because inactivation of Dot1l induced myeloid differentiation and severely inhibited the proliferation of MLL-AF9 leukemic cells (Fig. 1c,d ), shRNA constructs that rendered a growth or survival advantage to these cells were expected to be enriched in the screen after tamoxifen-induced Dot1l deletion. Analyses that compared hairpin frequency on day 9 and day 0 identified 934 significantly enriched shRNA constructs (a more than fourfold increase; P ≤ 0.05) after Dot1l deletion ( Fig. 1e and Supplementary Table 1) . Remarkably, we found three shRNAs targeting Sirt1 in this top 1% of enriched hairpins, making Sirt1 our leading Dot1l-antagonist candidate in MLL-AF9 leukemia (additional candidates are shown in Supplementary Fig. 1 ). SIRT1 mediates silencing of the MLL-AF9 leukemic program upon DOT1L inactivation To validate our genome-scale shRNA library screen results, we assessed whether the Sirt1 shRNAs that were selected for in the screen also suppressed Sirt1 expression. We also performed colony-forming assays. We found that the three shRNAs selected for in the screen suppressed Sirt1 expression and depletion of Sirt1 by these individual shRNAs (sh-Sirt1) maintained more MLL-AF9 driven blast-like colonies after Dot1l deletion, as compared to the control cultures transduced with shRNAs specific to luciferase (sh-LUC) ( Fig. 1f and Supplementary Fig. 1c,d ). Of note, depletion of Sirt1 alone did not influence the proliferation and blast-like colony potential of these leukemic cells. Additionally, we subjected the MLL-AF9 leukemia cells to EPZ4777, a selective small-molecular DOT1L inhibitor 29 , and we found that suppression of SIRT1 in MLL-AF9 leukemic cells reduced their sensitivity to DOT1L inhibition (Fig. 2a,b and Supplementary  Fig. 2) . Similarly, small-molecule inhibitors of SIRT1, including Ex527 and suramin 39 , desensitized MLL-AF9 leukemic cells to DOT1L inhibition, suggesting that SIRT1's enzymatic activity is important for the suppression of MLL-AF9 leukemic cells caused by DOT1L inhibition (Fig. 2c) .
In contrast, forced expression of SIRT1 by retroviral transduction resensitized the Sirt1-knockdown cells to EPZ4777 treatment (Fig. 2d,e) . Genes directly regulated by the MLL-AF9 fusion proteins are highly dependent on DOT1L for continued expression 8 . Therefore, we assessed whether depletion of Sirt1 protects MLL-AF9 cells by maintaining the expression of MLL-AF9-driven genes after DOT1L inhibition. We used microarrays and gene set enrichment analysis (GSEA) and found that the expression of the 'EPZ4777_down' gene set (978 genes; Supplementary Table 1) 29 was significantly (P < 0.01) maintained in EPZ4777 treated cells transduced with sh-Sirt1 (Fig. 2f) . Of interest, the top two rescued MLL-AF9 target genes (129 genes previously found to be bound by MLL-AF9 fusion proteins in mouse MLL-AF9 leukemia; Supplementary Table 1) 8 in the GSEA plot were Hoxa7 and Meis1. Reverse-transcription and quantitative PCR (RT-qPCR) confirmed that both Hoxa7 and Meis1 mRNA levels were drastically reduced upon DOT1L inhibition, whereas the expression of these two genes was significantly maintained by knockdown of Sirt1 in combination with DOTL1 inhibition (Fig. 2g) . Furthermore, we validated that ectopic expression of either Hoxa7 or Meis1 (or the combination) mimicked the effect of Sirt1 knockdown on reducing the sensitivity of MLL-AF9 leukemic cells to DOT1L inhibitors (Fig. 2h,i and Supplementary Fig. 3 ). These data validate Sirt1 as a crucial component of the cellular machinery that is essential for the suppression of the MLL-AF9 leukemic program upon DOTL1 inhibition.
SIRT1 is required for H3K9 deacetylation in response to DOT1L inhibition To investigate the mechanisms by which SIRT1 participates in silencing gene expression after DOT1L inhibition, we performed chromatin sh-LUC Enrichment score . Cells were cultured in the presence of EPZ4777 or DMSO for 6 d (f,g) and 9 d (a,c,e,h,i), respectively. Data represent the observed values and mean ±sd of three replicates (a,c,e,h,i) and three independent experiments (g). *P < 0.05; **P < 0.01 to control group using Student's t-test. npg immunoprecipitation coupled with high-throughput sequencing (ChIP-seq) for SIRT1 and H3K79me2 in mouse MLL-AF9 leukemia cells. We observed that EPZ4777 treatment increased the SIRT1 protein occupancy around the transcriptional start site, or TSS, of about one-third of annotated genes in the mouse genome ( Fig. 3a and Supplementary Figs. 4-6) . Notably, genes that were occupied by the SIRT1 protein after DOT1L inhibition were highly correlated with the initial levels of H3K79me2 (positively correlated with actively expressed genes) around their promoter proximal regions. Because SIRT1 is able to deacetylate multiple lysine positions in histones, we further performed ChIP-seq in mouse MLL-AF9 leukemia cells for H3K9ac, a chromatin substrate of SIRT1 that is highly associated with the TSSs of actively transcribed genes. We found that the distribution of H3K9ac at the active TSS overlapped with the loci where the recruitment of SIRT1 was observed after suppression of DOT1L (Fig. 3b) . Concomitantly with the increased SIRT1 occupancy on the active TSSs, we observed reduced H3K9ac on these loci after DOT1L inhibitor treatment (Fig. 3b) . Importantly, whereas depletion of Sirt1 minimally affected the level and distribution of H3K9ac under normal conditions, it completely blocked the loss of H3K9ac from the active npg TSS induced by DOT1L inhibitor treatment (Fig. 3c) . These results suggest that a function of DOT1L activity is to antagonize SIRT1-dependent deacetylation of H3K9 on the actively expressed genes.
To investigate whether SIRT1 is part of the mechanism for selective suppression of MLL fusion-driven gene expression after DOT1L inhibition, we compared SIRT1 occupancy after DOT1L inhibition at the MLL-AF9 targets (129 genes; Supplementary Table 1) 8 to SIRT1 occupancy after DOT1L inhibition at all actively expressed or silent genes (4,560 genes each; determined on the basis of the Affymetrix array) in mouse MLL-AF9 leukemic cells (Fig. 3d) . We observed a similar level of SIRT1 recruitment to MLL-AF9 targets as compared to the active genes upon EPZ4777 treatment; accordingly, there does not seem to be enhanced recruitment of SIRT1 to MLL-AF9 targets as compared to the larger group of active genes. However, when we compared the deacetylation of H3K9 upon DOT1L-inhibition, we identified a stronger loss of H3K9ac at the MLL-AF9 target genes replicates, and of three independent experiments (f). NS, not significant; *P < 0.05; **P < 0.01; ***P < 0.001 using Welch's t-test (a,i) and Student's t-test (c,e-h).
a r t i c l e s as compared to the active gene set (Fig. 3e) . Moreover, the removal of H3K9ac at MLL-AF9 targets was dependent on the presence of SIRT1, as knockdown of Sirt1 completely blocked the loss of H3K9ac at these TSSs induced by DOT1L inhibitor treatment (Fig. 3e) . These data show that the MLL-AF9 target genes are more sensitive to SIRT1-mediated histone deacetylation than other actively expressed genes.
Unique H3K9 epigenomic signature at MLL-AF9 target genes Our data identified a markedly stronger loss of H3K9ac at the MLL-AF9 target genes compared to that of other active gene loci after DOT1L inhibition. Notably, the majority of MLL-AF9 target genes in these leukemic cells possessed not only the highest H3K79me2 levels in the genome, as previously reported 8 , but they also showed elevated H3K9ac levels relative to other expressed loci (Fig. 4 and Supplementary Fig. 7) . We also note that H4K16ac (another known SIRT1 substrate) showed the same elevated pattern as H3K9ac (Supplementary Fig. 8 ).
In contrast, the MLL-AF9 target gene set exhibited a scattered distribution of these two histone markers among expressed genes in normal Lin − Sca1 + cKit + (LSK) hematopoietic stem/progenitor cells (Fig. 4b) . Because the leukemic cells used in this study were established through transformation of mouse LSK cells by MLL-AF9, our analyses suggest that the unique H3K9 epigenomic signature observed at the MLL-AF9 targets in these leukemias is attributable to the presence of MLL fusion oncoproteins at those loci. Indeed, we found that the genomic regions showing exaggerated H3K9ac hi status overlapped remarkably with the previously defined MLL-AF9-occupied peaks (Fig. 4c) 8 . Similarly, the increased H3K9ac level at MLL-AF9 target loci was confirmed in human MLL-AF9 cell line models (Fig. 4e-g ).
In fact, the two most well-studied MLL fusion target loci, the HOXA cluster and MEIS1, represent two of the largest H3K9ac hi domains in these MLL-r leukemias (Fig. 4h) .
Involvement of H3K9 methylation by SUV39H1 in SIRT1-mediated silencing of leukemic genes It has been reported [40] [41] [42] that mammalian SIRT1 physically interacts with other proteins that modify histones, and that it is found in complexes that mediate chromatin silencing. We therefore investigated dimethylation of histone 3 lysine 9 (H3K9me2) and trimethylation of histone 3 lysine 27 (H3K27me3), both of which have been connected to SIRT1-associated gene silencing [40] [41] [42] . Concomitantly with the reduction of H3K9ac, inhibition of DOT1L increased the amount of both H3K9me2 and H3K27me3 around the TSSs of MLL-AF9-bound genes, suggesting the potential involvement of multiple epigenetic repressive mechanisms in silencing the MLL fusion target loci (Fig. 5a) . Interestingly, depletion of Sirt1 completely blocked the removal of H3K9ac and selectively inhibited the accumulation of H3K9me2 at MLL-AF9 targets after DOT1L inhibition, whereas the gain of H3K27me3 at those loci remained largely unaffected (Fig. 5a) . Thus, SIRT1 function seems to be more crucial for H3K9 methylation than for H3K27 methylation after DOT1L inhibition at the MLL-AF9 targets.
To identify effectors responsible for SIRT1-dependent H3K9 methylation and gene silencing, we hypothesized that knockdown ) and six (e) replicates, and of ten mice per group (d). *P < 0.05 and # P < 0.01 compared to DMSO group; **P < 0.05 and ## P < 0.01 compared to both DMSO-and EPZ4777-alone groups using Student's t-test (a,b,d,e) and the Mantel-Cox test (c).
of such effectors would protect MLL-AF9 target gene expression after inactivation of Dot1l. We overlapped a list of SIRT1-interacting proteins (Supplementary Table 1) with the candidate antagonists of Dot1l, which we defined as genes having two or more shRNAs enriched more than twofold in the top 10% of the shRNA library screen described in Figure 1 . Remarkably, out of the 17 overlapping candidates, one of the genes, Suv39h1, encodes an H3K9 methyltransferase (Fig. 5b) . Suppression of Suv39h1 desensitized MLL-AF9 leukemic cells to DOT1L inhibition, thus phenocopying Sirt1 depletion (Fig. 5c) . Suppression of Suv39h1 resulted in a slight reduction of global H3K9me2 in MLL-AF9 leukemic cells and decreased the basal level of H3K9me2 at the TSSs of Hoxa7 and Meis1 (Fig. 5d,e) . Importantly, depletion of Suv39h1 completely blocked the accumulation of H3K9me2 (Fig. 5e) around the TSSs of Hoxa7 and Meis1 and significantly maintained the expression (Fig. 5f ) of these two MLL-AF9 targets after DOT1L inhibition. Thus, SUV39H1 is important for H3K9 methylation and silencing of the MLL-AF9-driven leukemic genes upon suppression of DOT1L. Furthermore, we found concomitant increases of both SIRT1 and SUV39H1 occupancy at Hoxa7 and Meis1 loci after DOT1L suppression (Fig. 5g,h and Supplementary Fig. 4) . Remarkably, the localization of SUV39H1 to these two MLL-AF9 target loci was dependent on the presence of SIRT1, because the suppression of Sirt1 diminished SUV39H1 binding to chromatin after DOT1L inhibition (Fig. 5h) . Because H3K9 methylation is frequently associated with chromatin compaction and heterochromatin, we next investigated whether SIRT1 and SUV39H1 affect the accessibility of chromatin by assay for transposase-accessible chromatin using sequencing (ATAC-seq) 43 . Although DOT1L inhibition significantly reduced transposase accessibility for the majority of MLL-AF9 targets ( Fig. 5i and Supplementary Figs. 9 and 10) , knockdown of either Sirt1 or Suv39h1 sustained the accessibility at these loci (Fig. 5i) .
Collectively, our data demonstrate that upon inhibition of DOT1L, SIRT1 is required for SUV39H1 chromatin localization and subsequent H3K9 dimethylation, which results in a less-accessible chromatin state in favor of gene silencing at genes directly regulated by MLL fusions (Supplementary Fig. 11 ).
Pharmacological activation of SIRT1 sensitizes MLL-r leukemia to DOT1L inhibition On the basis of the enlarged H3K9ac hi domains observed at the HOXA and MEIS1 loci in MLL-AF9 leukemias (Fig. 4c,d) , and because SIRT1 is required for deacetylation of H3K9, accumulation of H3K9 methylation and silencing of MLL-AF9 target genes, we explored whether pharmacological activation of SIRT1 enhances the efficacy of DOT1L inhibitors against MLL-r leukemias. Whereas EPZ4777 treatment alone suppressed the expression of Hoxa7 and Meis1, the combination of SRT1720 (a potent SIRT1 agonist) 44, 45 with EPZ4777 further diminished the expression of these two genes (Fig. 6a) . Concomitantly, we observed a further reduction of the H3K9ac levels at the TSSs of Hoxa7 and Meis1 loci in cells receiving the SRT1720 and EPZ4777 combination treatment (Fig. 6b) .
To examine the effect of ex vivo SRT1720 and EPZ4777 treatment on the ability of the treated cells to establish leukemia in mice, we transplanted equal numbers of viable cells from each treatment group into sublethally irradiated recipient mice (Fig. 6c) . Survival analysis revealed that SRT1720 pretreatment had no effect on leukemia latency, whereas EPZ4777 pretreatment significantly prolonged survival of injected mice (Fig. 6c) . Impressively, the onset of leukemia was further delayed in the case of SRT1720 and EPZ4777 combination treatment (median survival 49 d) (Fig. 6c) . Additionally, the percentage of MLL-AF9 leukemia cells in the peripheral blood was significantly lower in the mice that received cells treated with both SRT1720 and EPZ4777 as compared to mice that received cells that were treated with either small molecule individually (Fig. 6d) . Consistent with these results, the colony-forming potential (an in vitro assessment of leukemia-initiating capacity) of the combinatorially treated cells was drastically impaired as compared to cells treated with either the DOT1L inhibitor or SIRT1 agonist alone (Fig. 6e) .
Notably, SRT1720 treatment substantially reduced both the exposure time and dose of EPZ4777 required to induce an antiproliferative effect on MLL-AF9 leukemic cells (Fig. 6f) . Finally, we validated that addition of SRT1720 enhances the potency of EPZ4777 against human leukemia cell lines containing MLL-AF9 (Molm13) and MLL-AF4 (MV4-11 and SEMK2) gene translocations ( Fig. 6g and  Supplementary Fig. 12 ). Importantly, we did not observe a synthetic toxicity induced by EPZ4777 plus SRT1720 in non-MLL-r leukemia cells (Kasumi-1 and HL-60 cell lines). Together, our findings suggest that individuals with leukemia bearing MLL translocations may benefit from synergistic therapies that simultaneously target DOT1L and other epigenetic regulators such as SIRT1.
DISCUSSION
The dependency of the MLL fusion-driven gene expression program on DOT1L provides a potential therapeutic opportunity for MLL-r leukemias. A better understanding of DOT1L dependence might provide new therapeutic opportunities and also shed light on epigenetic mechanisms of gene regulation. Our genome-scale suppressor screen identified SIRT1 as important for DOT1L dependence in MLL-AF9-driven acute myeloid leukemia. We further demonstrate that DOT1L contributes to the maintenance of MLL fusion target gene expression by antagonizing an H3K9-mediated silencing mechanism instructed by SIRT1, which can be exploited to enhance the efficacy of DOT1L inhibitory therapy.
It has been proposed in S. cerevisiae that the presence of H3K79 methylation across the majority of the yeast genome marks regions of euchromatin, thereby relegating Sir2 binding to genomic regions, such as the mating type loci, that lack H3K79 methylation [46] [47] [48] [49] . Yeast Sir2 represses gene expression via deacetylation of local histones and promotion of histone modifications that facilitate heterochromatin formation 50, 51 . We found that inactivation of DOT1L in MLL-AF9 leukemia enhances SIRT1 occupancy at most genes that were previously decorated with H3K79 methylation, thus demonstrating an antagonistic relationship between DOT1L and SIRT1 in the mammalian epigenome much like that observed in yeast. However, substantial transcriptional silencing was observed only for limited loci that were highly enriched for genes bound by MLL-AF9, suggesting another layer of regulation. Along these lines, we found an enlarged H3K9ac hi signature at MLL-AF9-bound TSSs in both human and mouse MLL-r leukemias (Fig. 4) . Of note, a recent study discovered that the super elongation complex member AF9 (which also interacts with DOT1L) directly binds H3K9ac with high affinity 52 , thus providing a direct link between H3K9ac, H3K79me2, and active gene transcription. Notably, our data indicate that MLL fusion proteins prevent SIRT1-dependent deacetylation of H3K9 at least in part by constitutively recruiting DOT1L activity, thereby establishing an H3K79me2 hi and an H3K9ac hi histone modification state. It is also important to note that H4K16ac (another SIRT1 chromatin substrate associated with gene transcription) follows the same pattern as H3K9ac. This unique ability of MLL fusion complexes may uncouple their target genes from normal transcriptional regulation, thus enabling continuous expression of the leukemic program. Concomitantly with SIRT1-dependent histone deacetylation, we found that SUV39H1 mediated H3K9 dimethylation at MLL-AF9 target loci after DOT1L inhibition. Given that H3K9 methylation is associated with regions of heterochromatin 53 , we postulate that the ectopic expression of MLL fusion target genes in leukemia is dependent on open and accessible chromatin that is maintained by the ability of DOT1L and H3K79 methylation to repel SIRT1. This hypothesis is supported by the fact that, in addition to the changes in H3K9 modifications, we also found a SIRT1-dependent decrease in chromatin accessibility at MLL-AF9 target genes after DOT1L inhibition. Our findings are in agreement with previous reports showing that direct recruitment of SIRT1 to a promoter in mammalian cells suppresses gene expression through local facultative heterochromatin-mediated gene silencing 36, 51 . Therefore it appears that the MLL-AF9 fusion protein subverts an evolutionarily conserved mechanism of gene regulation and that a major role of DOT1L in the maintenance of MLL-r leukemias is to prevent SIRT1-dependent repressive mechanisms. Although we have focused extensively on H3K9 modifications, it should be noted that H3K27 trimethylation also increases at MLL-AF9 target genes after DOT1L inhibition (Fig. 5a) , and therefore DOT1L may be inhibiting multiple forms of gene repression.
Our study identifies a unique requirement for SIRT1 in silencing MLL-AF9 target genes (including the HOXA loci), specifically after DOT1L inhibition. This finding is in agreement with recent studies showing a role for SIRT1 in repressing MLL1-regulated genes (including HOXA genes) in normal hematopoietic cells 54, 55 . Other studies have reported that inhibitors of SIRT1 can suppress acute myeloid leukemias that harbor a FMS-related tyrosine kinase 3 (FLT3) internal tandem duplication through activation of the p53 pathway 56, 57 . Although we confirmed that modulation of p53 activity by SIRT1 does occur in the MLL-AF9 leukemia without FLT3 internal tandem duplications, this mechanism does not have a dominant role in the proliferation and survival of these leukemic cells (data not shown). Instead, our data demonstrate that SIRT1 is upstream of a series of changes in chromatin elicited by DOT1L inhibition in MLL-AF9 leukemia. Of note, SIRT1 directly recruits SUV39H1 and also activates SUV39H1's methyltransferase activity by deacetylating the SET domain 40 . This fact combined with our findings suggests that activation of SIRT1 might facilitate silencing of leukemogenic gene expression upon inhibition of DOT1L. Indeed, small-molecule activators of SIRT1 enhanced the efficacy of DOT1L inhibitor treatment against MLL-AF9 leukemic cells via a more rapid and complete silencing of MLL-AF9 target genes. These findings have immediate clinical relevance because DOT1L inhibitors are now in clinical trials for individuals with MLL-r leukemia. Important clinical responses have been noted with DOT1L inhibitor treatment alone 58 , but there is no doubt that combination approaches will be necessary. Our data suggest that targeting multiple epigenetic mechanisms controlling the expression of the MLL fusion-driven leukemogenic program should lead to greater therapeutic responses. Furthermore, this study also raises the key concern that incorrect combinations of anti-cancer therapeutics targeting epigenetic modulators, in this case DOT1L inhibitors with SIRT1 inhibitors (Fig. 2c) , may diminish clinical benefit owing to antagonism of DOT1L and SIRT1 inhibitors' downstream effects.
In summary, our findings demonstrate that DOT1L and H3K79me2 antagonize gene-repressive mechanisms to control mammalian gene expression. MLL-AF9 fusion proteins take advantage of this unique form of gene regulation to maintain a developmental program in cells in which the program should be repressed 59 . These studies prompt further experiments to define the developmental role of the DOT1L-SIRT1 axis in normal hematopoiesis, and to explore how specific combinations of histone modifications coordinate gene expression in a broader spectrum of biological processes such as body patterning, metabolism, aging and other cancers.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. All microarray and ChIP-seq data used in this study have been deposited into the National Center for Biotechnology Information (NCBI) Gene Expression Omnibus (GEO) with accession code GSE61022. 
